{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:29:40Z","timestamp":1758040180344,"version":"3.44.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.amjcard.2021.07.011","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T04:03:03Z","timestamp":1628827383000},"page":"150-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Meta-Analysis Addressing the Effect of Mineralcorticoid Receptor Antagonists on the Risk for New-Onset Atrial Fibrillation"],"prefix":"10.1016","volume":"157","author":[{"given":"Dimitrios","family":"Patoulias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christodoulos","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Toumpourleka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Doumas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2021.07.011_bib0001","doi-asserted-by":"crossref","first-page":"ITC33","DOI":"10.7326\/AITC201703070","article-title":"Atrial Fibrillation","volume":"166","author":"Zimetbaum","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2021.07.011_bib0002","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.117.309732","article-title":"Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes","volume":"120","author":"Staerk","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.amjcard.2021.07.011_bib0003","doi-asserted-by":"crossref","first-page":"i4482","DOI":"10.1136\/bmj.i4482","article-title":"Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis","volume":"354","author":"Odutayo","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2021.07.011_bib0004","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40256-019-00353-5","article-title":"Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial","volume":"20","author":"Neefs","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.amjcard.2021.07.011_bib0005","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1097\/CCM.0b013e31825b8be2","article-title":"Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery","volume":"40","author":"Pretorius","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.amjcard.2021.07.011_bib0006","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cardfail.2006.11.015","article-title":"Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure","volume":"13","author":"Gao","year":"2007","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2021.07.011_bib0007","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jacc.2011.11.063","article-title":"EMPHASIS-HF study investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (eplerenone in mild patients hospitalization and survival study in heart failure) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2021.07.011_bib0008","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1253\/circj.CJ-17-0323","article-title":"Double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of eplerenone in japanese patients with chronic heart failure (J-EMPHASIS-HF)","volume":"82","author":"Tsutsui","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.amjcard.2021.07.011_bib0009","first-page":"04964","article-title":"Finerenone reduces onset of atrial fibrillation in patients with chronic kidney disease and type 2 diabetes","volume":"S0735-1097","author":"Filippatos","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2021.07.011_bib0010","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.amjcard.2010.07.037","article-title":"Effect of combined spironolactone-\u03b2-blocker \u00b1 enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study)","volume":"106","author":"Dabrowski","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2021.07.011_bib0011","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jjcc.2010.11.006","article-title":"Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure","volume":"57","author":"Kimura","year":"2011","journal-title":"J Cardiol"},{"key":"10.1016\/j.amjcard.2021.07.011_bib0012","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/hr.2010.277","article-title":"Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats","volume":"34","author":"Kimura","year":"2011","journal-title":"Hypertens Res"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291492100669X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291492100669X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:39:20Z","timestamp":1757572760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000291492100669X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":12,"alternative-id":["S000291492100669X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2021.07.011","relation":{},"ISSN":["0002-9149"],"issn-type":[{"type":"print","value":"0002-9149"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-Analysis Addressing the Effect of Mineralcorticoid Receptor Antagonists on the Risk for New-Onset Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2021.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}